Researchers also observed elevated risks among patients treated in more recent time periods.
“Patients should be monitored indefinitely for second malignant neoplasms after the completion of their treatment for osteosarcoma,” Jean S. Lee, MD
, of the department of pediatrics at Benioff Children’s Hospital at University of California, San Francisco, and colleagues wrote. “The findings … may help to direct the type of surveillance screening for second malignant neoplasms in this population, with an emphasis on breast
and blood cancers